ATAI

#2139
AtaiBeckley Inc. Common Stock
4.3300 USD
-0.23%
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
4.3300
4.3300
Intervallo Annuale
3.2700
5.5000
Variazione giornaliera
-0.23%
Variazione Mensile
+28.49%
Variazione di 6 mesi
+9.62%
Variazione Annuale
+9.62%
Chiusura Precedente
4.3400
Apertura
4.3300
Minimo
4.3300
High
4.3300
Volume
64
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche
Trimestrale Annuale
  • Market Capitalization 1.5794 B
  • Employee 99
  • Founded 2018
  • CEO Florian Brand
  • Website www.ataibeckley.com
  • Headquarter Delaware, United States
  • FIGI BBG0107FR3K9
  • Industry Biotecnologia
Ricavi totali
Utile netto
Debito totale
Liquidità libera
Disponibilità liquide e mezzi equivalenti

AtaiBeckley Inc

atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany. The company's pharmaceutical candidates include dimethyltryptamine, -midomafetamine, and ibogaine, as well as EGX-121, 5-MeO-DMT, psilocin, inidascamine, deuterated mitragynine, EGX-A, EGX-B, deuterated etifoxine, and arketamine. In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In January 2023, atai Life Science's leading drug candidate at the time, arketamine, failed to meet its primary endpoint in a clinical trial. Following that, the company laid off 30% of its staff. Peter Thiel is a major investor in the company. atai Life Sciences has a 22.4% stake in Compass Pathways.

Notizie